|Articles|March 10, 2021
Application Note: AAV CQA analysis by SEC-MALS
Author(s)Wyatt Technology
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
2
FDA Clears Affinia’s AFTX-201 for Phase I/II BAG3 Cardiomyopathy Trial
3
Cellares Extends Cell Therapy Automation Beyond T Cell Therapies
4
Containment to Protection: Packaging Trends Impacting Biopharma
5